| Previous close | 44.87 |
| Open | 44.87 |
| Bid | 43.80 |
| Ask | 45.90 |
| Strike | 285.00 |
| Expiry date | 2025-01-17 |
| Day's range | 44.87 - 44.87 |
| Contract range | N/A |
| Volume | |
| Open interest | 210 |
ReutersBiogen beats quarterly profit estimates, Alzheimer's drug sales jump
The company also said its Alzheimer's drug Leqembi, developed with Japanese partner Eisai, recorded global sales of about $19 million, nearly tripling from the fourth quarter of 2023. The number of patients on Leqembi have increased nearly 2.5 times since the end of 2023, Biogen said. Biogen and Eisai also intend to increase their sales force as they aim for 100,000 patients by 2026.
Investor's Business DailyTwo Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
Two of Biogen's newest drugs walloped first-quarter sales expectations on Wednesday, and could help Biogen stock reverse a recent downtrend.
Insider MonkeyShould You Be Confident in Biogen (BIIB)?
Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter 2024 investor letter. A copy of the same can be downloaded here. During the quarter the strategy returned 11.8% net of fees compared to the S&P 500’s 10.6% return. The outperformance of the portfolio can be attributed to selection and […]
